Overview
- The company is offering 14,750,000 shares at $17 each and granted underwriters a 30‑day option for up to 2,212,500 additional shares.
- A concurrent private placement of 476,707 shares to affiliates of Goldman Sachs & Co. LLC is set at the IPO price and is contingent on the IPO closing.
- Shares were expected to begin trading on the Nasdaq Global Market on October 27 under the ticker MPLT, with the offering scheduled to close October 28 subject to customary conditions.
- Gross proceeds from the IPO and the private placement are expected to total approximately $258.9 million before underwriting discounts, commissions and expenses.
- MapLight is a clinical‑stage biotech focused on CNS disorders, with lead candidate ML‑007C‑MA in Phase 2 trials for schizophrenia and Alzheimer’s disease psychosis, and the offering is led by Morgan Stanley, Jefferies, Leerink Partners and Stifel.